Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis
ABSTRACT The 2022 World Health Organization guidelines recommend use of two core anti-tuberculosis (TB) drugs, bedaquiline (BDQ) and clofazimine (CFZ), for treatment of drug-resistant (DR)-TB. However, several mutated Mycobacterium tuberculosis (MTB) genes, conferring BDQ and CFZ resistance, have be...
Main Authors: | Jin Shi, Yuanyuan Liu, Tuoya Wu, Lu Li, Shujing Han, Xiao Peng, Yuanyuan Shang, Yongli Guo, Yu Pang, Mengqiu Gao, Jie Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2023-10-01
|
Series: | Microbiology Spectrum |
Subjects: | |
Online Access: | https://journals.asm.org/doi/10.1128/spectrum.00090-23 |
Similar Items
-
Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis
by: Yuhong Liu, et al.
Published: (2021-01-01) -
Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients
by: Yuanyuan Shang, et al.
Published: (2023-06-01) -
Rv1453 is associated with clofazimine resistance in Mycobacterium tuberculosis
by: Lei Zhang, et al.
Published: (2023-10-01) -
First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda
by: Jupiter Marina Kabahita, et al.
Published: (2022-05-01) -
Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study
by: Nazir A. Ismail, et al.
Published: (2018-02-01)